Medication info
Piotomin Tablets 15/850 milligrams

Piotomin Tablets 15/850 milligrams

Prescription medicationTablet
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Aju Pharmaceuticals Co., Ltd.
Appearance
White to grayish-white rectangular film-coated tablets
Packaging
30 tablets (10 tablets/PTP*3)
Approval status
Active

MFDS item code 201901634 · Approved 2019.03.18 · Insurance code 654005350

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this drug once daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from concomitant pioglitazone and metformin therapy: Patients switching from concomitant pioglitazone and metformin therapy to this drug may start at their previous doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching patients from another oral glucose-lowering agent to this drug. Any change in a type 2 diabetes treatment regimen may alter glycemic control, so caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this drug. After administration of this drug to a patient, or when increasing the dose, carefully monitor for adverse reactions associated with fluid retention. This drug should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is required to assess the adequacy of the treatment response. Ideally, treatment response should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the past 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Ingredients

Manufacturer
Aju Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes. It is effective in improving blood sugar levels when used in conjunction with dietary and exercise regimens. In particular, the combination of pioglitazone and metformin works together to support stable management of blood sugar. This helps in smoother diabetes management and can assist in the prevention of complications. It is recommended to use this medication for healthy blood sugar control.

Dosage and Administration

Adult dosage

For treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this drug once daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from concomitant pioglitazone and metformin therapy: Patients switching from concomitant pioglitazone and metformin therapy to this drug may start at their previous doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching patients from another oral glucose-lowering agent to this drug. Any change in a type 2 diabetes treatment regimen may alter glycemic control, so caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this drug. After administration of this drug to a patient, or when increasing the dose, carefully monitor for adverse reactions associated with fluid retention. This drug should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is required to assess the adequacy of the treatment response. Ideally, treatment response should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the past 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Precautions

This medication consists mainly of two components, the first of which is a drug that assists in blood sugar control. However, during the use of this medication, there is a very rare possibility of developing a serious condition called lactic acidosis, which occurs when there is excessive accumulation of lactic acid in the body. Lactic acidosis can occur more frequently in patients with impaired kidney function or those with issues related to the heart or lungs, or in patients with dehydration or infections, so caution is needed. Additionally, patients with liver dysfunction or those who consume excessive amounts of alcohol should avoid taking this medication. Initial symptoms of lactic acidosis may include fatigue, muscle pain, difficulty breathing, and abdominal pain; if such symptoms occur, immediate consultation with a physician is necessary. The second component is a drug that enhances the effect of insulin, and in some patients, the risk of worsening heart conditions such as heart failure may increase, so this medication should not be used in patients with severe heart conditions. This medication may cause edema due to fluid retention, and weight gain may occur, so it's important to regularly monitor the body's condition. Moreover, patients with a history of bladder cancer should carefully consider the risks of cancer recurrence associated with the use of this medication. This medication is not administered to patients with impaired kidney function, severe heart failure, active bladder cancer, pregnant or nursing women, or patients with certain genetic issues. Caution is also needed for patients before and after surgery, those with acute infections, or those in a state of malnutrition. While taking this medication, liver and kidney functions should be regularly monitored, and blood tests are needed as vitamin B12 deficiency may occur. Additionally, there is a risk of hypoglycemia, so care should be taken, especially in cases of irregular meals, excessive exercise, or use of other blood glucose-lowering agents. Alcohol may interact with this medication and increase risks, so it is advisable to avoid drinking while on treatment. When undergoing surgery or imaging examinations with contrast agents, it is essential to inform the physician about the use of this medication to decide on whether to discontinue its use. Finally, when administering this medication to elderly patients, kidney function should be closely monitored, and dosage should be adjusted accordingly; if any unusual symptoms or side effects occur, immediate consultation with a physician is necessary.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • malaise
  • myalgia
  • dyspnea
  • weakness
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 52 more
  • congestive heart failure
  • excessive and rapid weight changes
  • dyspnea
  • edema
  • upper respiratory infection
  • diarrhea
  • combined edema
  • peripheral edema
  • headache
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • nausea
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • decreased vision
  • diabetic macular edema
  • hepatic failure
  • edema
  • fluid retention
  • volumetric-related cases
  • fatigue
  • loss of appetite
  • discomfort in the right upper abdomen
  • dark urine
  • jaundice
  • abnormal liver function test values
  • macular edema
  • blurred vision
  • decreased vision
  • fractures
  • abnormal blood sugar levels
  • gastritis
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distention
  • gastroesophageal reflux disease
  • intragastric air retention
  • increased serum creatinine
  • increased blood urea
  • failure to control blood sugar
  • hypoglycemia
  • gross hematuria
  • urinary disorders
  • urgency in urination

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to keep it at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

White to grayish-white rectangular film-coated tablets

Package unit

30 tablets (10 tablets/PTP*3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.